Resolving the daratumumab interference with blood compatibility testing

Daratumumab (DARA), a promising novel therapy for multiple myeloma, is an IgG1κ monoclonal antibody that recognizes CD38 on myeloma cells. During routine compatibility testing, we observed that the plasma of five of five DARA‐treated patients demonstrated a positive antibody screen and panreactivity on red blood cell (RBC) panel testing. We hypothesized that the observed panreactivity reflected DARA binding to CD38 on reagent RBCs, and we investigated methods to prevent this binding.

[1]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[2]  J. Laubach,et al.  Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. , 2013 .

[3]  P. Richardson,et al.  Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study , 2012 .

[4]  Hon Cheung Lee,et al.  The Membrane-Bound Enzyme CD38 Exists in Two Opposing Orientations , 2012, Science Signaling.

[5]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[6]  W. Judd,et al.  Judd's Methods in Immunohematology , 2008 .

[7]  Özlem Demir,et al.  Erythrocyte CD38 as a prognostic marker in cancer , 2007, Hematology.

[8]  S. Waxman,et al.  Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. , 2001, Leukemia research.

[9]  F. Schuber,et al.  Probing ligand-induced conformational changes of human CD38. , 2000, European journal of biochemistry.

[10]  Martin L. Olsson,et al.  The Blood Group Antigen Factsbook , 1997 .

[11]  F. Malavasi,et al.  Human CD38, a cell‐surface protein with multiple functions , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  E. Zocchi,et al.  Structural role of disulfide bridges in the cyclic ADP‐ribose related bifunctional ectoenzyme CD38 , 1995, FEBS letters.

[13]  F. Malavasi,et al.  A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. , 1993, Biochemical and biophysical research communications.

[14]  T. Katada,et al.  NAD glycohydrolase specifically induced by retinoic acid in human leukemic HL-60 cells. Identification of the NAD glycohydrolase as leukocyte cell surface antigen CD38. , 1993, The Journal of biological chemistry.

[15]  村上 省三,et al.  Technical manual : 日本語版 , 1985 .